Waldemar Priebe

This inventor holds 36 USPTO granted patents and 9 published patent applications, plus 4 CIPO patents and 10 EPO patents, primarily in Cancer Treatment. Top assignees: The University of Texas System, Moleculin Biotech, Inc., Houston Pharmaceuticals, Inc.. Active years: 1989-2026.

USPTO Granted Patents = 36 (Patent Applications = 9)

% Patents Active = 83.3

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 13)

Average Co-Inventor Count = 4.0

ph-index = 7

Forward Citations = 197(Granted Patents)

Company Filing History:

29 out of 5,622

The University of Texas System

patents

5 out of 5

Moleculin Biotech, Inc.

patents

2 out of 3

Houston Pharmaceuticals, Inc.

The University of Mississippi

patents

6. 3 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1989-2026

Loading Chart...

Areas of Expertise:

Annamycin

Liposomal Formulations

Caffeic Acid Derivatives

Anthracycline Antibiotics

Cell Proliferative Diseases

DNA Binding Agents

Janus Tyrosine Kinase

Submicron Liposome Suspensions

Anticancer Activity

Thermally-Targeted Delivery

Iodo-Hexose Compounds

Halogenated Anthracyclines

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12734185 - Method of treating viral infections with hexose type monosaccharides and analogs thereof (2026-09-15),

2. 12257262 - Method of reconstituting liposomal annamycin (2025-03-25),

3. 12257261 - Preparation of preliposomal Annamycin lyophilizate (2025-03-25),

4. 11980634 - Method of reconstituting liposomal annamycin (2024-05-14),

5. 11951118 - Preparation of preliposomal annamycin lyophilizate (2024-04-09),

6. 11925654 - Esters of 2-deoxy-monosaccharides with anti proliferative activity (2024-03-12),

7. 11026960 - Esters of 2-deoxy-monosaccharides with anti proliferative activity (2021-06-08),

8. 10703721 - Caffeic acid derivatives and uses thereof (2020-07-07),

9. 10358439 - DNA binding agents with a minor groove binding tail (2019-07-23),

10. 10201554 - Esters of 2-deoxy-monosacharides with anti proliferative activity (2019-02-12),

11. 9096499 - Compounds for treatment of cell proliferative diseases (2015-08-04),

12. 9000179 - Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs) (2015-04-07),

13. 8927506 - Acetates of 2-deoxy monosaccharides with anticancer activity (2015-01-06),

14. 8779151 - Orally bioavailable caffeic acid related anticancer drugs (2014-07-15),

15. 8648102 - Compounds for treatment of cell proliferative diseases (2014-02-11),

Title: Waldemar Priebe - Innovator in Cancer Treatment

Introduction

Waldemar Priebe, based in Houston, TX, is a distinguished inventor with an impressive portfolio of 33 patents. His contributions to the field of cancer treatment through innovative methodologies have garnered attention and respect in academic and medical circles.

Latest Patents

Priebe's latest patents focus on groundbreaking methods for treating cancer. One notable patent, titled "Method of reconstituting liposomal annamycin," describes techniques for reconstituting lyophilized annamycin, a vital element in cancer therapies. Another significant invention, "Preparation of preliposomal annamycin lyophilizate," outlines a method for creating a preliposomal annamycin lyophilizate and emphasizes its composition's application in cancer treatment. These advancements are critical in enhancing the effectiveness of cancer therapeutics.

Career Highlights

Waldemar Priebe has had a noteworthy career, prominently associated with the University of Texas System, where he has made significant contributions to research and development in oncology. His extensive experience and dedication to innovation illustrate his commitment to improving patient outcomes through scientific discovery.

Collaborations

Throughout his career, Priebe has collaborated with esteemed colleagues such as Izabela Fokt and Roman Perez-Soler. These partnerships have further enriched the research landscape and facilitated the development of pioneering treatments in cancer care.

Conclusion

Waldemar Priebe continues to be a vital figure in the realm of cancer research and treatment. His innovative patents and collaborative efforts showcase a relentless pursuit of improving therapeutic options for patients, solidifying his legacy as a dedicated inventor in the medical field.